Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 4 | 5 |
1.1 List of Tables | 7 | 1 |
1.2 List of Figures | 7 | 2 |
2 Introduction | 9 | 15 |
2.1 Disease Introduction | 9 | 1 |
2.2 Symptoms | 10 | 1 |
2.3 Etiology | 10 | 1 |
2.4 Pathophysiology | 11 | 1 |
2.5 Epidemiology | 12 | 2 |
2.6 Diagnosis and Classification | 14 | 2 |
2.7 Prognosis and Disease Staging | 16 | 2 |
2.8 Treatment Options | 18 | 1 |
2.8.1 Surgery and Radiation Therapy | 18 | 1 |
2.8.2 Chemotherapy | 19 | 1 |
2.8.3 Hormonal Therapies | 19 | 1 |
2.8.4 Targeted Therapies | 20 | 1 |
2.8.5 Resistance to Pharmacological Therapies | 20 | 1 |
2.9 Treatment Guidelines | 21 | 3 |
3 Marketed Products | 24 | 15 |
3.1 Overview | 24 | 1 |
3.1.1 Herceptin (trastuzumab) Genentech | 24 | 2 |
3.1.2 Perjeta (pertuzumab) Genentech | 26 | 1 |
3.1.3 Afinitor (everolimus) Novartis | 27 | 1 |
3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate) Novartis | 28 | 1 |
3.1.5 Ibrance (palbociclib) Pfizer | 29 | 1 |
3.1.6 Ixempra (ixabepilone) Bristol-Myers Squibb | 29 | 1 |
3.1.7 Halaven (eribulin mesylate) Eisai | 30 | 1 |
3.1.8 Avastin (bevacizumab) Genentech | 31 | 1 |
3.1.9 Kadcyla (ado-trastuzumab emtansine) Genentech | 31 | 1 |
3.2 Marketed Products Heatmap | 32 | 1 |
3.2.1 Herceptin | 33 | 2 |
3.2.2 Perjeta | 35 | 1 |
3.2.3 Afinitor | 35 | 1 |
3.2.4 Tykerb/Tyverb | 35 | 1 |
3.2.5 Ibrance | 36 | 1 |
3.2.6 Ixempra | 37 | 1 |
3.2.7 Halaven | 37 | 1 |
3.3 Measuring the Effectiveness of Treatment | 38 | 1 |
3.4 Conclusion | 38 | 1 |
4 Pipeline Products | 39 | 14 |
4.1 Overall Pipeline | 39 | 1 |
4.1.1 Pipeline by Molecular Target | 40 | 3 |
4.2 Clinical Trials | 43 | 1 |
4.2.1 Failure Rate | 43 | 2 |
4.2.2 Patient Enrollment and Clinical Trial Size | 45 | 4 |
4.2.3 Duration | 49 | 3 |
4.3 Competitive Clinical Trials Metrics Analysis | 52 | 1 |
5 Promising Drug Candidates in Pipeline | 53 | 16 |
5.1 Abemaciclib Eli Lily | 53 | 1 |
5.1.1 Abemaciclib Forecast | 53 | 1 |
5.2 Buparlisib Novartis | 54 | 1 |
5.2.1 Buparlisib Forecast | 55 | 1 |
5.3 Lynparza (olaparib) AstraZeneca | 56 | 1 |
5.3.1 Lynparza Forecast | 56 | 1 |
5.4 Neratinib Puma Biotechnology | 57 | 1 |
5.4.1 Neratinib Forecast | 58 | 1 |
5.5 Ribociclib Novartis | 59 | 1 |
5.5.1 Ribociclib Forecast | 60 | 1 |
5.6 NeuVax (nelipepimut-S) Galena Biopharma | 60 | 1 |
5.7 Veliparib AbbVie | 61 | 1 |
5.8 Niraparib Tesaro | 62 | 1 |
5.9 Talazoparib BioMarin | 62 | 1 |
5.10 Alpelisib Novartis | 63 | 1 |
5.11 Atezolizumab Roche | 64 | 1 |
5.12 Entinostat Syndax | 65 | 1 |
5.13 Margetuximab MacroGenics | 66 | 1 |
5.14 Taselisib Genentech | 66 | 1 |
5.15 OBI-822/821 OBI Pharma | 67 | 1 |
5.16 Heat Map for Pipeline Products | 67 | 2 |
6 Market Forecast to 2021 | 69 | 14 |
6.1 Geographical Markets | 69 | 1 |
6.2 Asia-Pacific Market | 69 | 2 |
6.3 India | 71 | 1 |
6.3.1 Treatment Usage Patterns | 71 | 1 |
6.3.2 Annual Cost of Therapy | 72 | 1 |
6.3.3 Market Size | 73 | 1 |
6.4 China | 73 | 1 |
6.4.1 Treatment Usage Patterns | 73 | 2 |
6.4.2 Annual Cost of Therapy | 75 | 1 |
6.4.3 Market Size | 76 | 1 |
6.5 Australia | 77 | 1 |
6.5.1 Treatment Usage Patterns | 77 | 1 |
6.5.2 Annual Cost of Therapy | 78 | 1 |
6.5.3 Market Size | 79 | 1 |
6.6 Japan | 80 | 1 |
6.6.1 Treatment Usage Patterns | 80 | 1 |
6.6.2 Annual Cost of Therapy | 81 | 1 |
6.6.3 Market Size | 82 | 1 |
7 Drivers and Barriers for the Disease Market | 83 | 3 |
7.1 Drivers | 83 | 1 |
7.1.1 Increased Uptake of Targeted and Combination Therapies for Breast Cancer | 83 | 1 |
7.1.2 Growth and Aging of Populations to Increase the Incidence | 83 | 1 |
7.1.3 Launch of Premium-Priced Products with Greater Efficacy than Existing Therapies | 83 | 1 |
7.2 Barriers | 83 | 1 |
7.2.1 High Level of Competition | 83 | 1 |
7.2.2 Problems with the Reimbursement of Premium-Priced Therapeutics will Limit their Uptake | 84 | 1 |
7.2.3 Delayed Presentation of Symptoms, Lack of Access and Awareness to Hamper Proper Treatment | 84 | 1 |
7.2.4 Multiple Drugs to Lose Patent Protection in Forecast Period | 85 | 1 |
8 Deals and Strategic Consolidations | 86 | 10 |
8.1 Licensing Deals | 86 | 3 |
8.1.1 EUSA Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib | 89 | 1 |
8.1.2 Sprint Bioscience Enters Licensing Agreement with Bayer HealthCare | 89 | 1 |
8.1.3 Takeda Enters Licensing Agreement with ImmunoGen | 90 | 1 |
8.1.4 Oncothyreon Enters Licensing Agreement with Array BioPharma for ONT-380 | 90 | 1 |
8.1.5 Halozyme Therapeutics Enters Licensing Agreement with Janssen Biotech | 90 | 1 |
8.1.6 CTI BioPharma Enters Licensing Agreement with Servier for Pixuvri | 90 | 1 |
8.2 Co-development Deals | 91 | 3 |
8.2.1 Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration | 94 | 1 |
8.2.2 MacroGenics Enters Agreement with Merck | 94 | 1 |
8.2.3 Color Genomics Partners with University of California Health | 94 | 1 |
8.2.4 Lycera Enters Co-development Agreement with Celgene | 95 | 1 |
8.2.5 Roche Enters Agreement with Oryzon to Develop Epigenetics-Based Medicines | 95 | 1 |
8.2.6 Tracon Enters Co-development Agreement with Santen | 95 | 1 |
9 Appendix | 96 | 76 |
9.1 All Pipeline Drugs by Phase of Development | 96 | 57 |
9.1.1 Discovery | 96 | 4 |
9.1.2 Preclinical | 100 | 16 |
9.1.3 IND/CTA-filed | 116 | 1 |
9.1.4 Phase I | 117 | 18 |
9.1.5 Phase II | 135 | 13 |
9.1.6 Phase III | 148 | 4 |
9.1.7 Pre-registration | 152 | 1 |
9.2 Market Forecasts to 2021 | 152 | 3 |
9.2.1 Asia-Pacific | 152 | 1 |
9.2.2 China | 153 | 1 |
9.2.3 India | 153 | 1 |
9.2.4 Australia | 154 | 1 |
9.2.5 Japan | 154 | 1 |
9.3 Bibliography | 154 | 9 |
9.4 Abbreviations | 163 | 4 |
9.5 Research Methodology | 167 | 4 |
9.5.1 Secondary Research | 168 | 1 |
9.5.2 Marketed Product Profiles | 168 | 1 |
9.5.3 Late-Stage Pipeline Candidates | 168 | 1 |
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products | 168 | 1 |
9.5.4.1 Overall Pipeline | 169 | 1 |
9.5.4.2 Clinical Trials | 169 | 1 |
9.5.4.2.1 Failure Rate | 169 | 1 |
9.5.4.2.2 Clinical Trial Size | 169 | 1 |
9.5.4.2.3 Clinical Trial Duration | 169 | 1 |
9.5.4.2.4 Clinical trial Endpoint Analysis | 169 | 1 |
9.5.5 Forecasting Model | 170 | 1 |
9.5.6 Deals Data Analysis | 170 | 1 |
9.6 Expert Panel Validation | 171 | 1 |
9.7 Contact Us | 171 | 1 |
9.8 Disclaimer | 171 | 1 |